Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Non-Current Liabilities: 2015-2024

Historic Total Non-Current Liabilities for Intellia Therapeutics (NTLA) over the last 4 years, with Dec 2024 value amounting to $189.1 million.

  • Intellia Therapeutics' Total Non-Current Liabilities was N/A to $189.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $189.1 million, marking a year-over-year change of. This contributed to the annual value of $189.1 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q4 2024, Intellia Therapeutics' Total Non-Current Liabilities is $189.1 million, which was down 27.43% from $260.5 million recorded in Q4 2022.
  • Over the past 5 years, Intellia Therapeutics' Total Non-Current Liabilities peaked at $260.5 million during Q4 2022, and registered a low of $189.1 million during Q4 2024.
  • In the last 2 years, Intellia Therapeutics' Total Non-Current Liabilities had a median value of $238.1 million in 2022 and averaged $229.5 million.